王永全,李富娟

随着微生物组学的不断发展，越来越多的研究揭示了体内微生物组的重要性。女性阴道内寄生着庞大而复杂的微生物组，这些微生物对维持健康和稳态起着关键作用。本文综述了阴道微生物组在宫颈癌发展与治疗中的作用。

阴道微生物组；宫颈癌；发展；治疗

[1] Ravel J, Gajer P, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1(Suppl 1):4680-7. doi: 10.1073/pnas.1002611107. [2] Sepich-Poore GD, Zitvogel L, et al. The microbiome and human cancer. Science. 2021 Mar 26;371(6536):eabc4552. doi: 10.1126/science.abc4552. [3] Rajagopala SV, Vashee S, et al. The Human Microbiome and Cancer. Cancer Prev Res (Phila). 2017 Apr;10(4):226-234. doi: 10.1158/1940-6207.CAPR-16-0249. [4] Nunn KL, Forney LJ. Unraveling the Dynamics of the Human Vaginal Microbiome. Yale J Biol Med. 2016 Sep 30;89(3):331-337. [5] Łaniewski P, Barnes D, et al. Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women. Sci Rep. 2018 May 15;8(1):7593. doi: 10.1038/s41598-018-25879-7. [6] Lewis FMT, Bernstein KT, et al. Vaginal Microbiome and Its Relationship to Behavior, Sexual Health, and Sexually Transmitted Diseases. Obstet Gynecol. 2017 Apr;129(4):643-654. doi: 10.1097/AOG.0000000000001932. [7] Nelson TM, Borgogna JC, et al. Cigarette smoking is associated with an altered vaginal tract metabolomic profile. Sci Rep. 2018 Jan 16;8(1):852. doi: 10.1038/s41598-017-14943-3. [8] Sabo MC, Balkus JE, et al. Association between vaginal washing and vaginal bacterial concentrations. PLoS One. 2019 Jan 24;14(1):e0210825. doi: 10.1371/journal.pone.0210825. [9] Romero R, Hassan SS, et al. The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women. Microbiome. 2014 Feb 3;2(1):4. doi: 10.1186/2049-2618-2-4. [10] Jespers V, Kyongo J, et al. A longitudinal analysis of the vaginal microbiota and vaginal immune mediators in women from sub-Saharan Africa. Sci Rep. 2017 Sep 20;7(1):11974. doi: 10.1038/s41598-017-12198-6. [11] Sung H, Ferlay J, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. [12] Moscicki AB, Schiffman M, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 2012 Nov 20;30 Suppl 5(0 5):F24-33. doi: 10.1016/j.vaccine.2012.05.089. [13] Shulzhenko N, Lyng H, et al. Ménage à trois: an evolutionary interplay between human papillomavirus, a tumor, and a woman. Trends Microbiol. 2014 Jun;22(6):345-53. doi: 10.1016/j.tim.2014.02.009. [14] Gillet E, Meys JF, et al. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis. BMCInfect Dis. 2011 Jan 11;11:10. doi: 10.1186/1471-2334-11-10. [15] Guo YL, You K, et al. Bacterial vaginosis is conducive to the persistence of HPV infection. Int J STD AIDS. 2012 Aug;23(8):581-4. doi: 10.1258/ijsa.2012.011342. [16] Mitra A, Lee YS, et al.Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. Sci Rep. 2015 Nov 17;5:16865. doi: 10.1038/srep16865. [17] Audirac-Chalifour A, Torres-Poveda K, et al. Cervical Microbiome and Cytokine Profile at Various Stages of Cervical Cancer: A Pilot Study. PLoS One. 2016 Apr 26;11(4):e0153274. doi: 10.1371/journal.pone.0153274. [18] Gao W, Weng J, et al. Comparison of the vaginal microbiota diversity of women with and without human papillomavirus infection: a cross-sectional study. BMC Infect Dis. 2013 Jun 10;13:271. doi: 10.1186/1471-2334-13-271. [19] Lee JE, Lee S, et al. Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort. PLoS One. 2013 May 22;8(5):e63514. doi: 10.1371/journal.pone.0063514. [20] Brotman RM, Shardell MD, et al. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J Infect Dis. 2014 Dec 1;210(11):1723-33. doi: 10.1093/infdis/jiu330. Epub 2014 Jun 18. [21] Di Paola M, Sani C, et al. Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection. Sci Rep. 2017 Aug 31;7(1):10200. doi: 10.1038/s41598-017-09842-6. [22] Jelic MD, Mandic AD, et al. Oxidative stress and its role in cancer. J Cancer Res Ther. 2021 Jan-Mar;17(1):22-28. doi: 10.4103/jcrt.JCRT_862_16. [23] Ebrahimi S, Soltani A, et al. Oxidative stress in cervical cancer pathogenesis and resistance to therapy. J Cell Biochem. 2019 May;120(5):6868-6877. doi: 10.1002/jcb.28007. [24] Williams VM, Filippova M, et al. Human papillomavirus type 16 E6* induces oxidative stress and DNA damage. J Virol. 2014 Jun;88(12):6751-61. doi: 10.1128/JVI.03355-13. [25] Zhang R, Shen C, et al. Dysregulation of host cellular genes targeted by human papillomavirus (HPV) integration contributes to HPV-related cervical carcinogenesis. Int J Cancer. 2016 Mar 1;138(5):1163-74. doi: 10.1002/ijc.29872. [26] Zhang L, Wu J, et al. The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. Mol Cancer. 2015 Apr 17;14:87. doi: 10.1186/s12943-015-0361-x. [27] Gutiérrez-Hoya A, Soto-Cruz I. Role of the JAK/STAT Pathway in Cervical Cancer: Its Relationship with HPV E6/E7 Oncoproteins. Cells. 2020 Oct 15;9(10):2297. doi: 10.3390/cells9102297. [28] Alexander JL et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat. Rev. Gastroenterol. Hepatol 14, 356–365 (2017). [29] Wilkinson EM, Ilhan ZE, et al. Microbiota-drug interactions: Impact on metabolism and efficacy of therapeutics. Maturitas. 2018 Jun;112:53-63. doi: 10.1016/j.maturitas.2018.03.012. [30] Taneva E, Sinclair S, et al. Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics. JCI Insight. 2018 Jul 12;3(13):e99545. doi: 10.1172/jci.insight.99545. [31] hurman AR, Schwartz JL, et al. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings. PLoS One. 2019 May 20;14(5):e0217229. doi: 10.1371/journal.pone.0217229. [32] Maduro JH, Pras E, et al. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev. 2003 Dec;29(6):471-88. doi: 10.1016/s0305-7372(03)00117-8. [33] Okawa T, Niibe H, et al. Effect of LC9018 combined with radiation therapy on carcinoma of the uterine cervix. A phase Ⅲ, multicenter, randomized, controlled study. Cancer. 1993 Sep 15;72(6):1949-54. doi: 10.1002/1097-0142(19930915)72:6<1949::aid-cncr2820720626>3.0.co;2-w. [34] Chase D, Goulder A, et al. The vaginal and gastrointestinal microbiomes in gynecologic cancers: a review of applications in etiology,symptoms and treatment. Gynecol Oncol. 2015 Jul;138(1):190-200. doi: 10.1016/j.ygyno.2015.04.036. [35] Morris L, Do V, et al. Radiation-induced vaginal stenosis: current perspectives. Int J Womens Health. 2017 May 2;9:273-279. doi: 10.2147/IJWH.S106796. [36] Bai J, Daniel G, et al. Pilot Study of Vaginal Microbiome Using QIIME 2™ in Women With Gynecologic Cancer Before and After Radiation Therapy. Oncol Nurs Forum. 2019 Mar 1;46(2):E48-E59. doi: 10.1188/19. [37] Kandati K, Belagal P, et al. Role of probiotics in the management of cervical cancer: An update. Clin Nutr ESPEN. 2022 Apr;48:5-16. doi: 10.1016/j.clnesp.2022.02.017. [38] Li Y, Yu T, et al. Vaginal Microbiota and HPV Infection: Novel Mechanistic Insights and Therapeutic Strategies. Infect Drug Resist. 2020 Apr 30;13:1213-1220. doi: 10.2147/IDR.S210615. [39] Wang H, Ma Y, et al. Associations of Cervicovaginal Lactobacilli With High-Risk Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia, and Cancer: A Systematic Review and Meta-Analysis. J Infect Dis. 2019 Sep 13;220(8):1243-1254. doi: 10.1093/infdis/jiz325. [40] Motevaseli E, Shirzad M, et al. Normal and tumour cervical cells respond differently to vaginal lactobacilli, independent of pH and lactate. J Med Microbiol. 2013 Jul;62(Pt 7):1065-1072. doi: 10.1099/jmm.0.057521-0. [41] Marrazzo JM, Dombrowski JC, et al. Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. Clin Infect Dis. 2019 Feb 15;68(5):803-809. doi: 10.1093/cid/ciy554. [42] Chavoustie SE, Gersten JK, et al. A Phase 3, Multicenter, Prospective, Open-Label Study to Evaluate the Safety of a Single Dose of Secnidazole 2 g for the Treatment of Women and Postmenarchal Adolescent Girls with Bacterial Vaginosis. J Womens Health (Larchmt). 2018 Apr;27(4):492-497. doi: 10.1089/jwh.2017.6500. [43] van Nood E, Vrieze A, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. [44] Chen T, Xia C, et al. Dysbiosis of the rat vagina is efficiently rescued by vaginal microbiota transplantation or probiotic combination. Int J Antimicrob Agents. 2021 Mar;57(3):106277. doi: 10.1016/j.ijantimicag.2021.106277.

点击下载PDF